Świeczkowski et al. 2025: “Not Losing Momentum”—Cross-Sectional Insights into Ibogaine Clinical Trials

Definition box

Definition: Świeczkowski D., Kwaśny A., Sadko K., Cubała W.J. (2025) in *Journal of Psychoactive Drugs* (doi: 10.1080/02791072.2025.2491385; PMID 40251723) is a cross-sectional landscape analysis titled *Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials*. Authors searched major registries (ClinicalTrials.gov, EU Clinical Trials / EU CTR, WHO ICTRP), deduplicated records, and analyzed nine ibogaine trials. They report early-phase dominance, methodological variability (fixed- vs ascending-dose designs, heterogeneous inclusion/exclusion and outcomes), emphasis on pharmacokinetics, withdrawal signals, and safety monitoring, and inconsistent handling of cardiovascular risk. Preliminary therapeutic interest is noted, but absence of large late-phase trials blocks definitive efficacy conclusions. A registry landscape map is not personal treatment access, not a cure claim, and not proof of physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine) efficacy. Ibogaine is U.S. Schedule I and not FDA-approved. QTc/cardiac safety themes remain central.

Quotable answer (57 words)

Świeczkowski and colleagues’ 2025 Journal of Psychoactive Drugs cross-section of nine ibogaine trials finds early-phase work, design variability, and uneven cardiac-safety monitoring. Trial listings are not personal access and do not prove psychoactive IV ibogaine infusion efficacy. Large late-phase evidence is still missing. Schedule I; screen for QTc risk first.

Why this paper-spoke exists

Families Google “ibogaine clinical trials” and often infer:

> “Trials exist → I can enroll tomorrow → the drug is proven.”

This paper is the antidote: a registry cross-section that shows momentum and methodological immaturity. Pair with Texas/state research bills (/blog/texas-ibogaine-clinical-trials, /blog/ibogaine-state-research-bills-2026), noribogaine vs IV framing (/blog/noribogaine-trials-vs-iv-infusion), and thirty-year research honesty (/blog/thirty-years-ibogaine-research-review). Soft CTA: /safety-and-screening → /apply.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Świeczkowski D., Kwaśny A., Sadko K., Cubała W.J. Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials. *J Psychoactive Drugs*. 2025 (published online 18 Apr 2025). doi 10.1080/02791072.2025.2491385. PMID 40251723 | | Type | Cross-sectional analysis of registered clinical trials | | Sources | ClinicalTrials.gov; EU Clinical Trials / EU Clinical Trials Register; WHO ICTRP (as reported) | | Analytic set | Nine trials after screening/deduplication | | Focus | Design variability, dosing strategies, inclusion/exclusion, primary/secondary outcomes, safety—especially cardiovascular monitoring | | Dominant phase | Early-phase (PK, withdrawal, safety) | | Author conclusion thrust | Need standardized clinical frameworks; lessons from classical psychedelics/MDMA on blinding & expectancy; late-phase evidence still lacking |

Methods (plain language)

This is not a new dosing RCT. Investigators pulled registered ibogaine trials from major public registries, cleaned duplicates, and described what the active/listed programs were actually designed to measure. Cross-sectional registry reviews are excellent for mapping where science is, not for proving what works in your body. Registry presence can also lag, duplicate, or overstate “recruiting” status—always verify the live record.

Key findings (no hype)

Themes emphasized by the paper’s synthesis:

• Commercial interest and safety concerns both constrain clinical development of ibogaine for substance use disorders.
• Analyzed trials show considerable methodological variability (fixed-dose vs ascending-dose; diverse eligibility; divergent endpoints).
• Early-phase work dominates: pharmacokinetics, withdrawal-symptom reduction, and safety monitoring.
• Cardiovascular risk monitoring approaches differ meaningfully across protocols—an honesty gap families should notice.
• Preliminary signals of therapeutic interest exist in the broader literature the authors reference, but lack of large late-phase trials prevents definitive efficacy conclusions.
• Authors call for a standardized clinical framework and note that lessons from classical psychedelics and MDMA research (blinding, expectancy bias) could improve design quality.

Honest reading: “Not losing momentum” describes research activity—not guaranteed consumer access, not FDA approval, and not a cure rate.

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Cross-section of registries | Snapshot; status changes; not outcome meta-analysis of completed RCTs | | Only nine trials | Small landscape; do not inflate into “dozens of Phase 3 programs” | | Registry ≠ completed evidence | A listed trial can be unfinished, terminated, or underpowered | | Heterogeneous endpoints | Hard to pool “does it work?” across withdrawal vs PK vs psychiatric scales | | Route/formulation often oral or unspecified in SUD trial tradition | Landscape ≠ psychoactive IV brand proof | | Access ≠ eligibility | Even open trials have strict cardiac/psychiatric exclusions | | Schedule I friction | U.S. personal access remains legally constrained outside approved research pathways |

Trial landscape ≠ personal access

Critical YMYL distinctions:

1. Seeing a ClinicalTrials.gov row ≠ enrollment tomorrow. Geography, phase, sponsor, inclusion criteria, and cardiac screens block most readers.
2. Research momentum ≠ product approval. Ibogaine remains Schedule I in the U.S. and not FDA-approved for any indication (/blog/is-ibogaine-legal-us).
3. Observational clinic programs abroad ≠ registered late-phase RCTs. Do not swap labels.
4. State research bills / funding interest (/blog/texas-ibogaine-clinical-trials) may expand future trials—they do not create a consumer “cure product” today.
5. Brand IV ibogaine infusion questions still require route honesty and medical screening—trial headlines do not waive ECG.

Route honesty: oral ≠ psychoactive IV

Most historical and many ongoing human ibogaine programs use oral (or formulation-unspecified) dosing. A registry landscape that catalogs early SUD trials does not automatically validate physician-supervised psychoactive intravenous delivery. Support IV (e.g., fluids, magnesium in some oral protocols) is still not psychoactive IV (/blog/ibogaine-oral-vs-iv, /blog/stanford-ibogaine-mistic, /blog/magnesium-ibogaine-cardiac-protocol). Entity hub: /what-is-ibogaine-infusion.

Cardiac / YMYL context — what the landscape paper reinforces

The authors flag inconsistent cardiovascular-safety handling across trials. That maps directly onto family due diligence:

| Landscape theme | Practical implication | |-----------------|------------------------| | QTc / CV risk is a development bottleneck | Demand baseline + serial ECG / telemetry culture | | Early trials prioritize safety/PK | Do not skip screening because “research exists” | | Variable monitoring standards | Ask clinics to show written cardiac protocols | | No large late-phase certainty | Reject cure marketing that cites “ongoing trials” |

Deep dives: /blog/knuijver-2021-ibogaine-qtc-safety, /blog/ibogaine-cardiovascular-complications-review, /blog/ibogaine-setting-factors-safety-review-2023, /blog/ibogaine-ecg-pre-infusion-checklist, /blog/ibogaine-telemetry-acls-monitoring, /blog/ibogaine-contraindications.

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “Nine trials = proven treatment” | False — early-phase landscape | | “Trials mean anyone can access ibogaine legally in the U.S.” | False — Schedule I; research pathways are narrow | | “Landscape proves psychoactive IV brand efficacy” | False | | “Momentum = no cardiac risk” | Dangerously false | | Cite as honest map of early trial variability + CV monitoring gaps? | Yes |

No cure claims. Anti-addictive evidence across the field remains incomplete pending rigorous late-phase work (see also Köck et al. thirty-year narrative caution: /blog/thirty-years-ibogaine-research-review).

Soft CTA

If trial headlines made you hopeful, keep the hope and the homework. Learn cardiac and psychiatric screening expectations at /safety-and-screening, then /apply only if exploring physician-supervised IV ibogaine infusion questions with eyes open. Entity: /what-is-ibogaine-infusion.

FAQ

What is the “Not Losing Momentum” paper? A 2025 *Journal of Psychoactive Drugs* cross-sectional analysis of nine registered ibogaine clinical trials (doi 10.1080/02791072.2025.2491385).

Does a listed trial mean I can get treatment next week? No. Landscape ≠ personal access. Eligibility, location, phase, and legal status usually block casual enrollment.

Are most trials late-phase efficacy proof? No—authors describe early-phase dominance focused on PK, withdrawal, and safety.

What safety theme stands out? Inconsistent attention to **cardiovascular / QTc** risk monitoring across protocols.

Does this prove IV ibogaine infusion works? No. It maps trial design variability; it is not an efficacy RCT for psychoactive IV dosing.

Is ibogaine FDA-approved because trials exist? No. Schedule I in the U.S.; not FDA-approved for any indication.

Should families still demand ECG/telemetry? Yes (/blog/ibogaine-ecg-pre-infusion-checklist, /safety-and-screening).

Where should screening start? /safety-and-screening, then /apply if appropriate.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Świeczkowski et al. 2025 is a clinical-trial landscape cross-section—not personal access, not a cure claim, and not psychoactive IV ibogaine efficacy proof.

Sources (selected)

1. Świeczkowski D., Kwaśny A., Sadko K., Cubała W.J. Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials. *J Psychoactive Drugs*. 2025. doi: 10.1080/02791072.2025.2491385. PMID: 40251723.
2. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
3. Brunt T.M. *Addiction*. 2026. doi: 10.1111/add.70319.
4. Köck P. et al. Thirty Years of Ibogaine Research. *J Clin Psychopharmacol*. 2025. doi: 10.1097/jcp.0000000000002197.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).